ATRC - AtriCureAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $62.65 | Open | $63.01 |
| Volume | 362.6K | Market Cap | 1.157B |
| Yield | Last Dividend |
| AtriCure Announces Labeling Expansion fo... | 01/04/21 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure to Participate in Upcoming Pipe... | 11/19/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial... | |
| Atrial Fibrillation Market: Product Deve... | 11/18/20 |
| "Atrial Fibrillation Market" New Report Published by Insight Partners market: Global Analysis and Forecast by 2020-2027. Major industry players operat... | |
| Insights on the Left Atrial Appendage Cl... | 11/09/20 |
| DUBLIN--(BUSINESS WIRE)--The "Left Atrial Appendage Closure Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchA... | |
| Latest Report on Cardiac Ablation Market... | 11/07/20 |
| Cardiac Ablation Market Growing at a CAGR of 12.40% and Expected to Reach $2.4 Billion by 2025. Cardiac ablation is a procedure to destroy tissues in ... | |
| AtriCure (NASDAQ:ATRC) Downgraded by Bid... | 10/24/20 |
| BidaskClub downgraded shares of AtriCure (NASDAQ:ATRC) from a sell rating to a strong sell rating in a report published on Thursday, BidAskClub report... | |
| BidaskClub Downgrades AtriCure (NASDAQ:A... | 10/24/20 |
| AtriCure (NASDAQ:ATRC) was downgraded by equities research analysts at BidaskClub from a ???sell??? rating to a ???strong sell??? rating in a report i... | |
| AtriCure (NASDAQ:ATRC) Cut to ???Strong ... | 10/23/20 |
| AtriCure (NASDAQ:ATRC) was downgraded by equities research analysts at BidaskClub from a ???sell??? rating to a ???strong sell??? rating in a research... | |
| AtriCure (NASDAQ:ATRC) Cut to Strong Sel... | 10/23/20 |
| BidaskClub lowered shares of AtriCure (NASDAQ:ATRC) from a sell rating to a strong sell rating in a research report released on Thursday morning, BidA... | |
| Radiofrequency Ablation Systems Market 2... | 10/20/20 |
| Radiofrequency Ablation Systems Market By Type (Unipolar Radiofrequency Ablation, Bipolar Radiofrequency Ablation), Application (Arrhythmia, Obstructi... | |
| AtriCure to Announce Third Quarter 2020 ... | 10/13/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| Atrial Fibrillation Market Growth Insigh... | 10/12/20 |
| Atrial fibrillation also referred to as AFib or AF is a medical condition that causes irregular heartbeat (arrhythmia) and which can further lead to b... | |
| Cardiac Ablation Sales Market Growth and... | 10/07/20 |
| All information provided in the report is derived from trusted industrial sources. Global Cardiac Ablation Sales Market research reports finds market ... | |
| Kerrisdale: AtriCure Inc. (ATRC) Revenue... | 09/30/20 |
| Kerrisdale Capital is short shares of AtriCure, Inc. Q2 2020 hedge fund letters, conferences and more We are short shares of AtriCure, a $1.9bn medica... | |
| AtriCure to Participate at the Morgan St... | 09/01/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure Announces Angie Wirick as Chief... | 08/06/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure, Inc. (ATRC) CEO Mike Carrel on... | 07/28/20 |
| AtriCure, Inc. (NASDAQ:ATRC) Q2 2020 Earnings Conference Call July 28, 2020 4:30 P.M. | |
| AtriCure Reports Second Quarter 2020 Fin... | 07/28/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| The Daily Biotech Pulse: FDA Nod For Roc... | 05/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC ... | |
| The Daily Biotech Pulse: Gilead Signs Ma... | 05/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acce... | |
| AtriCure Announces Proposed Public Offer... | 05/11/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure Announces Results from CONVERGE... | 05/08/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure Announces Investor Update Webca... | 04/30/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure Reports First Quarter 2020 Fina... | 04/29/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| AtriCure Announces Preliminary Financial... | 04/09/20 |
| MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendag... | |
| The Daily Biotech Pulse: Epizyme's Tazem... | 02/14/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs F... | |
| The Daily Biotech Pulse: Deciphera Cance... | 02/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) ... | |
| The Daily Biotech Pulse: J&J Intensifies... | 02/12/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) ... | |
| The Daily Biotech Pulse: LogicBio Slappe... | 02/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) ... | |
| The Daily Biotech Pulse: Novartis Earnin... | 01/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) ... | |
| Buy rating | 02/24/21 |
| Needham maintains Buy rating and raises Price Target from $63.00 to $74.00 | |
| Strong Buy rating | 02/24/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $65.00 to $78.00 | |
| Strong Buy rating | 12/14/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $60.00 to $65.00 | |
| Date | 2021-02-23 (AMC) | Est. (EPS/Rev.) | ($0.28)/ 58.1M |
| Actual (EPS/Rev.) | $-0.18/ $57.73 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
